Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

− Results show delivery of high radiation doses to tumours compared with normal organs.

Championing the future of nuclear medicine

Heather Jacene, MD, assistant chief of Nuclear Medicine and Molecular Imaging at Brigham and Women’s Hospital, clinical director of Nuclear Medicine at Dana-Farber Cancer Institute, and associate professor of Radiology at Harvard Medical School in Boston, Massachusetts, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).